Day: May 12, 2020

Novavax Reports First Quarter 2020 Financial Results

  • CEPI increases investment up to $388 million for NVX‑CoV2373 vaccine development & manufacturing
  • NVXCoV2373 Phase I trial initiating in May with preliminary results in July
  • NanoFlu recently achieved all primary endpoints in pivotal Phase 3 clinical trial
  • Company